Greenwave as you mention ,there are other alternatives,other than licsening deals ,such as arranging finances,Grant Chamberlain,principal of One Venture and IMM director could possibly play a large role in that.Its my belief that big bio could sponsor a collaboration as has been the case in some recent deals,and the IMM scientific team lead by Triebel conduct the study,hence the pre phase 1 trial arrangements currently underway.Who Better than possibly the doctor himself and his team , to carry out the trial.
Ann: Progress towards clinical development of IMP761, page-15
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.3¢ | $537.2K | 1.728M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 43201 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 541277 | 36 |
View Market Depth
| Last trade - 12.38pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
